Aurobindo Pharma to invest Rs. 300 crores for expanding its mammalian cell culture manufacturing facility of CuraTeQ Biologics which is a fully owned subsidiary of the Drug maker.
There was a meeting held on 1st september where all the board members agreed to expand its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements. The capital expenditure for ramping up capacities is estimated to be around Rs.300 crores.
The new site facility is likely to be fully operational by FY 2026 depending on regulatory approvals and other factors.
Aurobindo Pharma wants to enter in contract manufacturing operations for biologicals for effective utilization of capacities and augmenting the business prospects in this area as the global biologics contract manufacturing demand is growing at 8 to 10% rate.
The company further said the board of its another wholly owned subsidiary, Auro Vaccines, has also approved exploring possibilities to offer contract manufacturing service to global vaccine developers to effectively utilise its existing manufacturing capacity.
